WEST LAFAYETTE, IN, July 9, 2018 — Bioanalytical Systems, Inc. (NASDAQ:BASI) has announced that its Board of Directors agreed unanimously on July 2, 2018, to appoint John E. Sagartz, DVM, PhD, DACVP, as a director.
“We’re delighted to welcome John to our board,” said Dr. Gregory C. Davis, BASi’s Chairman of the Board. “For several years, BASi has extensively collaborated with Seventh Wave Laboratories, the company John founded and led for over fifteen years, so we have firsthand appreciation of his strong scientific background, impeccable leadership, and entrepreneurial vision. John will be an invaluable source of guidance as we move forward with this venture.”
BASi and Seventh Wave Laboratories recently signed an asset purchase agreement (APA) joining operations to provide broader solutions and greater scientific expertise to clients.
Dr. Sagartz began his career as a toxicologic pathologist at Searle/Monsanto in 1996, and held positions of increasing responsibility as section head, director, preclinical development site head, and fellow, following Monsanto’s merger with Pharmacia. After Pfizer’s acquisition of Pharmacia in 2003, Dr. Sagartz founded Seventh Wave Laboratories where he served as president and CEO, and most recently as president and chief strategy officer.
Dr. Sagartz is an adjunct associate professor of Comparative Medicine at St. Louis University’s College of Medicine and currently serves on the board of directors of the Missouri Biotechnology Association. He received his Bachelor of Science and Doctor of Veterinary Medicine degrees from Kansas State University and, after completing residency training in anatomic pathology, earned his Doctor of Philosophy from The Ohio State University.
“I’m excited to participate as a director of BASi,” said Dr. Sagartz. “We have a unique opportunity to shape a newly combined organization, and position it as a quality resource for bringing new products to patients and creating value for all of our stakeholders.”
About Bioanalytical Systems, Inc.
BASi is a pharmaceutical development company providing contract research services and monitoring instruments to the world’s leading drug development companies and medical research organizations. The Company focuses on developing innovative services and products that increase efficiency and reduce the cost of taking a new drug to market. Visit www.BASinc.com for more information about BASi.
This release may contain forward-looking statements that are subject to risks and uncertainties including, but not limited to, risks and uncertainties related to changes in the market and demand for our products and services, the development, marketing and sales of products and services, changes in technology, industry standards and regulatory standards, and various market and operating risks detailed in the company’s filings with the Securities and Exchange Commission.
Jill Blumhoff, BASi Chief Financial Officer & Vice President of Finance